Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.

Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a KD of 10?8 M or less; activates and/or increases CD27 mediated NF-?B activity; stimulates CD4+ and/or CD8+ T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-? by CD4+ and/or CD8+ T cells. The present disclosure also provides a method for preparing and using said antibody.

Abstract: A composition including an immunoconjugate and a chemotherapeutic agent. The immunoconjugate includes 1) one or more interleukins, and 2) an Fc domain consisting of a first Fc subunit and a second Fc subunit. The first Fc subunit associates with the second Fc subunit to form a dimer. The one or more interleukins are fused to the Fc domain and the chemotherapeutic agent includes a fluorouracil and/or an oxaliplatin.

Abstract: Provided is an immunoconjugate useful in inhibiting tumor growth, and a composition and/or protein mixture comprising the immunoconjugate. Also provided are methods for the production of the immunoconjugate, as well as pharmaceutical uses of the immunoconjugate in inhibiting tumor growth, including but not limited to treatment of cancers.

Abstract: Proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

Abstract: An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.

Abstract: The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a KD of 10?8 M or less; activates and/or increases CD27 mediated NF-?B activity; stimulates CD4+ and/or CD8+ T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-? by CD4+ and/or CD8+ T cells. The present disclosure also provides a method for preparing and using said antibody.

Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.

Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.

Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.